BIT (ASX) BIT Charting

Originally posted by jebby: ↑

Aquestion to AI Copilot
How long does it usually take to analyse thousands of data sets in a phase 2 trial by a biotech company using athird party to analyse the results?

The Answer
Analyzing thousandsof data sets in a Phase2 clinical trial is a complex process that involves several factors. While the exact duration can vary based on the specifics of the trial, here are some key considerations:
Data Collection: Before analysis begins, data must be collected from the trial participants. This includes information related to the treatment, patient demographics, adverse events, and other relevant variables. The time required for data collection depends on the trial’s duration and the number of participants.
Data Cleaning and Preparation: Raw data often contains errors, missing values, and inconsistencies. Biotech companies need to clean and preprocess the data to ensure its quality. This step involves identifying and correcting errors, imputing missing values, and standardizing formats. The time needed for data cleaning depends on the complexity of the data and the efficiency of the process.
Statistical Analysis: Biostatisticians analyze the data using statistical methods. They assess treatment efficacy, safety, and other relevant endpoints. The complexity of the statistical models, the volume of data, and the specific analyses required (e.g., survival analysis, regression, subgroup analyses) impact the time spent on this step.
Third-Party Involvement: When a third-party organization is responsible for data analysis, additional coordination is necessary. The biotech company and the third party must communicate, share data securely, and agree on analysis plans. The time taken depends on the efficiency of collaboration and the third party’s workload.
Quality Control and Validation: Rigorous quality control checks are essential to ensure accurate results. Biotech companies review the analysis outputs, validate statistical code, and verify findings. This process ensures data integrity but adds to the overall timeline.
Reporting and Interpretation: Once the analysis is complete, the results need to be summarized in reports or scientific publications. Interpretation, discussion, and drawing meaningful conclusions take time.
Regulatory Submissions: If the trial results are intended for regulatory submissions (e.g., to obtain drug approval), additional time is needed to prepare documentation and address any queries from regulatory agencies.
Summary:
Duration: The entire process can take several weeks to several months, depending on the trial’s complexity, data volume, and organizational efficiency.
Variability: Each trial is unique, so there is no fixed timeframe. Some trials may be expedited, while others require more time.
Collaboration: Effective communication and collaboration between the biotech company and the third party are crucial for timely analysis.
Remember thataccurate and thorough analysis is essential for making informed decisions indrug development. Rushing the process can compromise the quality of resultsand impact patient safety and scientific validity

Expand

Nice first post Jebby, I think the best part I took from that is this section I have in GREEN!

Lack of organisational skills and terrible at time lines!

After 20 plus years of being involved in bio-tech, why the hell would miller write "COMING WEEKS" surely she would know better than that!

So that Leeds to my conclusion that something else is going on in regards to maybe - peer review taking place, BP and the talked of privacy agreements, or they are just shite At completing their jobs and have absolutely zero regard for the share holders, THE ONES PAYING THEIR INFLATED WAGES!

No.	Vol.	Price($)
4	259000	4.5¢

No.

Vol.

Price($)

259000

4.5¢

Price($)	Vol.	No.
4.6¢	17361	1

Price($)

Vol.

No.

4.6¢

17361

No.	Vol.	Price($)
4	259000	0.045
1	200000	0.044
3	415000	0.043
3	322000	0.042
4	287000	0.041

No.

Vol.

Price($)

259000

0.045

200000

0.044

415000

0.043

322000

0.042

287000

0.041

Price($)	Vol.	No.
0.047	200000	1
0.048	308915	1
0.050	21000	1
0.051	96225	3
0.052	1527335	2

Price($)

Vol.

No.

0.047

200000

0.048

308915

0.050

21000

0.051

96225

0.052

1527335

(20min delay)
Last 4.6¢		Change 0.001(2.22%)		Mkt cap ! $41.50M

Open	High	Low	Value	Volume
4.4¢	4.7¢	4.4¢	$31.64K	708.3K

BIT Charting, page-1383

Strike Energy secures $153 million for Perth Basin gas projects

Emyria's Empax Centre chosen for mental health clinical trial

Belararox delineates another porphyry in Argentina at Tambo South

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

BIT Charting, page-1383

Top Stories

Strike Energy secures $153 million for Perth Basin gas projects

Emyria's Empax Centre chosen for mental health clinical trial

Belararox delineates another porphyry in Argentina at Tambo South

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News